Actinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025

Reuters11-04

Actinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025

Actinium Pharmaceuticals Inc. announced that new preclinical data for its lead antibody radioconjugate program, ATNM-400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 10-14, 2025. The data, to be presented in poster session 4 on December 11, will highlight the anti-tumor activity of ATNM-400 in tamoxifen- and trastuzumab-resistant breast cancer models. According to the company, preclinical results demonstrate efficacy of ATNM-400 as a monotherapy and in combination with standard-of-care therapies across breast cancer, prostate cancer, and non-small cell lung cancer models. The company states that these findings support further development of ATNM-400 in solid tumors, particularly in patient populations with resistance to current hormone and HER2-targeted therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY14212) on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580736006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580736006","market":"fut","top_or_hot":-1,"title":"Actinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Actinium Pharmaceuticals Inc. announced that new preclinical data for its lead antibody radioconjugate program, ATNM-400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 10-14, 2025. The data, to be presented in poster session 4 on December 11, will highlight the anti-tumor activity of ATNM-400 in tamoxifen- and trastuzumab-resistant breast cancer models. According to the company, preclinical results demonstrate efficacy of ATNM-400 as a monotherapy and in combination with standard-of-care therapies across breast cancer, prostate cancer, and non-small cell lung cancer models. The company states that these findings support further development of ATNM-400 in solid tumors, particularly in patient populations with resistance to current hormone and HER2-targeted therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY14212) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Actinium Pharmaceuticals Inc. announced that new preclinical data for its lead antibody radioconjugate program, ATNM-400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 10-14, 2025. The data, to be presented in poster session 4 on December 11, will highlight the anti-tumor activity of ATNM-400 in tamoxifen- and trastuzumab-resistant breast cancer models. According to the company, preclinical results demonstrate efficacy of ATNM-400 as a monotherapy and in combination with standard-of-care therapies across breast cancer, prostate cancer, and non-small cell lung cancer models. The company states that these findings support further development of ATNM-400 in solid tumors, particularly in patient populations with resistance to current hormone and HER2-targeted therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY14212) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATNM","symbol_name":"Actinium Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL30cyKb:1","article_id":"2580736006","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580736006","pubTimestamp":1762259453,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actinium Pharmaceuticals Inc. announced that new preclinical data for its lead antibody radioconjugate program, ATNM-400, will be presented at the 2025 San Antonio Breast Cancer Symposium , scheduled for December 10-14, 2025. The data, to be presented in poster session 4 on December 11, will highlight the anti-tumor activity of ATNM-400 in tamoxifen- and trastuzumab-resistant breast cancer models. According to the company, preclinical results demonstrate efficacy of ATNM-400 as a monotherapy and in combination with standard-of-care therapies across breast cancer, prostate cancer, and non-small cell lung cancer models. The company states that these findings support further development of ATNM-400 in solid tumors, particularly in patient populations with resistance to current hormone and HER2-targeted therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-ge","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATNM":"Actinium Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Actinium Pharmaceuticals在SABCS 2025上公布了针对耐药乳腺癌的有希望的ATNM-400数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNM":0.9},"content_text":"Actinium Pharmaceuticals Unveils Promising ATNM-400 Data for Drug-Resistant Breast Cancer at SABCS 2025\n    \n\n        Actinium Pharmaceuticals Inc. announced that new preclinical data for its lead antibody radioconjugate program, ATNM-400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 10-14, 2025. The data, to be presented in poster session 4 on December 11, will highlight the anti-tumor activity of ATNM-400 in tamoxifen- and trastuzumab-resistant breast cancer models. According to the company, preclinical results demonstrate efficacy of ATNM-400 as a monotherapy and in combination with standard-of-care therapies across breast cancer, prostate cancer, and non-small cell lung cancer models. The company states that these findings support further development of ATNM-400 in solid tumors, particularly in patient populations with resistance to current hormone and HER2-targeted therapies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY14212) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580736006","isCrawlerRequest":true}